Blue­bird says it has more good news for its gene ther­a­py safe­ty, but a pric­ing dis­agree­ment in Ger­many will spur lay­offs

Fol­low­ing two safe­ty scares back in Feb­ru­ary re­gard­ing its sick­le-cell pro­gram, blue­bird bio’s gene ther­a­py ap­pears to be in the clear.

Ex­ecs from the Cam­bridge …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER